secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001493152-24-017209
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma amends agreement with Cytovance to raise ownership cap from 4.9% to 9.9%
--------------------------------------------------------------------------------

- Cytovance's beneficial ownership limit raised from 4.9% to 9.9% of GT Biopharma's outstanding common stock.
- Amendment effective April 25, 2024; all other terms of the Aug 24, 2022 Settlement and Investment Agreement unchanged.
- Excess shares above 9.9% cap to be issued in quarterly installments with 10-day prior notice from GTBP.
- Executed by GTBP Executive Chairman Michael Breen and Cytovance CFO David Knauss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/0001493152-24-017209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer